Specific Biological Therapy in Autoimmune Disease
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.author | Shusterman, Yonatan | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Szentmiklósi, József András | |
| dc.contributor.opponentdept | Kenézy Kórház, Központi Aneszteziológiai és Intezív Terápiás Osztály | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.date.accessioned | 2020-10-15T08:11:50Z | |
| dc.date.available | 2020-10-15T08:11:50Z | |
| dc.date.created | 2020-02-27 | |
| dc.description.abstract | Autoimmune disorders have been showing an increasing prevalence in recent decades with women affected more often. The rapid advancements in efficacy and variety of biological drugs have shown to be helpful in reducing the chronic inflammatory process underlying such diseases. This review examines which of these agents are currently used with the highest efficacy in the treatment of rheumatoid arthritis, Psoriasis and Crohns disease. | hu_HU |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 60 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/296740 | |
| dc.language.iso | en | hu_HU |
| dc.subject | Autoimmune Disease | hu_HU |
| dc.subject | TNF inhibitors | hu_HU |
| dc.subject | IL-17 antagonists | hu_HU |
| dc.subject | IL-12/23 antagonists | hu_HU |
| dc.subject | rheumatoid arthritis | hu_HU |
| dc.subject | psoriasis | |
| dc.subject | Crohn disease | |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | Specific Biological Therapy in Autoimmune Disease | hu_HU |